WebSep 14, 2009 · 4. Roberts JR, Eustis C, Devore R, et al: Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg 72:885-888, 2001. 5. Martin J, Ginsberg RJ, Abolhoda A, et al: Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right … WebApr 10, 2024 · Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial Signal Transduct Target Ther . 2024 Apr 10;8(1):146. doi: 10.1038/s41392-023-01355-1.
Neoadjuvant chemotherapy plus nivolumab with or without …
WebConsensus 1: preoperative use of neoadjuvant immunotherapy with or without platinum-based chemotherapy for patients with resectable stage IB‒IIIA NSCLC may be considered. In 1994, Rosell and Roth published two classic prospective randomized controlled trials of NCT for stage IIIA NSCLC, and since then a number of studies since have demonstrated … WebJul 12, 2024 · For neoadjuvant therapy in patients with non-small cell lung cancer, the major pathologic response of primary tumors may be an assessable and reliable surrogate measure of survival. Few studies ... sfdr official text
Neoadjuvant PD-1 blockade in non-small cell lung cancer OTT
WebJun 17, 2024 · Although neoadjuvant immunotherapy is currently only approved for use in combination with chemotherapy in triple-negative breast cancer and non–small cell lung cancer, it is anticipated that ongoing and future clinical trials will further define the role of neoadjuvant immunotherapy in many cancer types. WebApr 11, 2024 · Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens ... WebNeoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review. Background: Approximately 30% of all cases of nonsmall-cell lung cancer (NSCLC) are of a locally advanced (IIIA or IIIB) stage. sfdrs 1live radio